Verteporfin | CAS:129497-78-5

Chemscene社は、高品質な低分子化合物を提供しているメーカーです。
Chemscene社のVerteporfin(CAS:129497-78-5)をご紹介します。

※本製品は研究用です。研究用以外には使用できません。

Name:Verteporfin; CL 318952
Cat. No. :CS-1950
CAS No. :129497-78-5
Formula:C41H42N4O8
M. Wt. : 718.79
Solubility:DMSO: 5.6 mg/mL

Verteporfin is a benzoporphyrin derivative monoacid ring A, and can inhibit the activity of YAP.In Vitro: Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 µM, 2.11 µM, and 5.61 µM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and paclitaxel (PTX) shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T[2]. In Vivo: Verteporfin (10 mg/kg, c.s.c.) and dasatinib significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen[1].

Pan W, et al. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression. Cell Physiol Biochem. 2016;39(2):481-90. Morishita T, et al. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget. 2016 Aug 2.